Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M. File

Showing results (91-100 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Antimicrobial Agents|June 11, 2017
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time pointThomas M File, Paul B Eckburg, George H Talbot, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
The Journal of Emergency Medicine|May 15, 2007
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremiaMark I Neuman, Meera Kelley, Marvin B Harper, et al.
Infection Control and Hospital Epidemiology|June 3, 2020
Impact of the expansion of antimicrobial stewardship services during transitions of care at an academic hospitalStephanie T Zampino, Paula A Politis, Susan M Fosnight, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 17, 2013
Evaluation and use of a rapid Staphylococcus aureus assay by an antimicrobial stewardship programTamara L Trienski, Heather L Barrett, Timothy R Pasquale, et al.
The Journal of Infectious Diseases|September 14, 2020
Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSACynthia L Sears, William G Powderly, Paul G Auwaerter, et al.
Current Medical Research and Opinion|September 24, 2004
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaThomas M File, Gary Milkovich, Alan M Tennenberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 2, 2019
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline AntibioticSteven Opal, Thomas M File, Tom van der Poll, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
International Journal of Antimicrobial Agents|December 16, 2020
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairmentOliver A Cornely, Thomas M File, Lynne Garrity-Ryan, et al.
Pageof 16

Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Antimicrobial Agents|June 11, 2017
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time pointThomas M File, Paul B Eckburg, George H Talbot, et al.
International Journal of Antimicrobial Agents|January 25, 2005
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File, Javier Garau, Michael R Jacobs, et al.
The Journal of Emergency Medicine|May 15, 2007
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremiaMark I Neuman, Meera Kelley, Marvin B Harper, et al.
Infection Control and Hospital Epidemiology|June 3, 2020
Impact of the expansion of antimicrobial stewardship services during transitions of care at an academic hospitalStephanie T Zampino, Paula A Politis, Susan M Fosnight, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 17, 2013
Evaluation and use of a rapid Staphylococcus aureus assay by an antimicrobial stewardship programTamara L Trienski, Heather L Barrett, Timothy R Pasquale, et al.
The Journal of Infectious Diseases|September 14, 2020
Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSACynthia L Sears, William G Powderly, Paul G Auwaerter, et al.
Current Medical Research and Opinion|September 24, 2004
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaThomas M File, Gary Milkovich, Alan M Tennenberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 2, 2019
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline AntibioticSteven Opal, Thomas M File, Tom van der Poll, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
International Journal of Antimicrobial Agents|December 16, 2020
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairmentOliver A Cornely, Thomas M File, Lynne Garrity-Ryan, et al.
Pageof 16